Peanut Protein and Increased Antigen-Specific IgG1 Levels

Doses used in studies

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

systemic adverse eventsIncreased risk
Systemic adverse events were fewer in Group 30 mg compared with Group 300 mg.
from: Peanut Oral Immunotherapy Using 30 and 300 mg Maintenance Doses.
Overall tolerabilityReported
A 30 mg maintenance dose for P-OIT significantly increases the threshold over strict avoidance, clinically similarly to 300 mg, and may allow for a simplified and safer immunotherapy regimen and fewer treatment dropouts.
from: Peanut Oral Immunotherapy Using 30 and 300 mg Maintenance Doses.
treatment discontinuation / withdrawalReported
In Group 30 mg, 15 of 17 patients completed DBPCFC (two of 17 withdrew). In Group 300 mg, 12 of 17 patients completed DBPCFC (five of 17 withdrew). In Group Avoid, 12 of 17 completed DBPCFC (five of 17 were lost to follow-up).
from: Peanut Oral Immunotherapy Using 30 and 300 mg Maintenance Doses.

1 of 1 paper

Peanut Oral Immunotherapy Using 30 and 300 mg Maintenance Doses.